The role of icatibant—the B2 bradykinin receptor antagonist—in life-threatening laryngeal angioedema in the ED

Bartal, Carmi; Zeldetz, Vladimir; Stavi, Vered; Barski, Leonid

doi:10.1016/j.ajem.2014.08.055

Cited by 17 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intubation and tracheotomy were avoided in several cases following icatibant administration. 35,[40][41][42]46,48 Icatibant was not successful in one case; however, the reason for lack of benefit in this case is unknown. 38 Two case series comparing icatibant-treated patients with those previously treated with standard therapies found statistically significant improvements in time to complete symptom resolution.…”

Section: Discussionmentioning

confidence: 92%

“…16,33 Case reports/series involving the management of ACEI-IA with icatibant are summarized in Table 3. [34][35][36][37][38][39][40][41][42][43][44][45] Icatibant successfully resolved symptoms in 25 of the 26 cases (96%). Treatment with standard therapy and icatibant did not improve symptoms in one case leading to intubation and ICU management with eventual resolution and discharge a few days after presentation.…”

Section: Icatibantmentioning

confidence: 96%

“…Summary of Select Published Case Reports/Series of Icatibant for ACEI-Induced Angioedema Treatment [34][35][36][37][38][39][40][41][42][43][44][45]. …”

mentioning

confidence: 99%

See 2 more Smart Citations

Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor–Induced Angioedema

2015

View full text Add to dashboard Cite

ACEI-IA is typically a self-limiting event. First-line therapies include ACEI discontinuation, observation, and supportive medications (eg, corticosteroids, antihistamines, and epinephrine). Symptom progression can be life-threatening and may require interventions such as tracheotomy and intubation. Off-label use of FFP and medications approved for hereditary angioedema have resulted in rapid resolution of symptoms and avoidance of intubation. Among these agents, icatibant has the most supporting evidence and has been incorporated into practice guidelines and algorithms as a second-line agent for serious life-threatening ACE-IA.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Icatibantmentioning

confidence: 96%

See 1 more Smart Citation

Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor–Induced Angioedema

2015

View full text Add to dashboard Cite

show abstract

“…Reduces ischaemic infarct volume, reduces postischaemic neuronal oedema, improves neuronal function recovery, reduces blood brain barrier disruption, protects memory deficits, angioedema treatment, blocks propagation of inflammation. 50,51,[91][92][93] Icatibant Extracellular calcium sensing receptor antagonist P41180 36…”

Section: Id Rank Effects Reference Drugbankmentioning

confidence: 99%

Combined network pharmacology and virtual reverse pharmacology approaches for identification of potential targets to treat vascular dementia

Lagunin

Ivanov

Gloriozova

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Dementia is a major cause of disability and dependency among older people. if the lives of people with dementia are to be improved, research and its translation into druggable target are crucial. Ancient systems of healthcare (Ayurveda, Siddha, Unani and Sowa-Rigpa) have been used from centuries for the treatment vascular diseases and dementia. this traditional knowledge can be transformed into novel targets through robust interplay of network pharmacology (NetP) with reverse pharmacology (RevP), without ignoring cutting edge biomedical data. This work demonstrates interaction between recent and traditional data, and aimed at selection of most promising targets for guiding wet lab validations. PROTEOME, DisGeNE, DISEASES and DrugBank databases were used for selection of genes associated with pathogenesis and treatment of vascular dementia (VaD). The selection of new potential drug targets was made by methods of NetP (DIAMOnD algorithm, enrichment analysis of KEGG pathways and biological processes of Gene Ontology) and manual expert analysis. The structures of 1976 phytomolecules from the 573 Indian medicinal plants traditionally used for the treatment of dementia and vascular diseases were used for computational estimation of their interactions with new predicted VaD-related drug targets by RevP approach based on PASS (Prediction of Activity Spectra for Substances) software. We found 147 known genes associated with vascular dementia based on the analysis of the databases with gene-disease associations. Six hundred novel targets were selected by NetP methods based on 147 gene associations. The analysis of the predicted interactions between 1976 phytomolecules and 600 NetP predicted targets leaded to the selection of 10 potential drug targets for the treatment of VaD. The translational value of these targets is discussed herewith. Twenty four drugs interacting with 10 selected targets were identified from DrugBank. These drugs have not been yet studied for the treatment of VaD and may be investigated in this field for their repositioning. The relation between inhibition of two selected targets (GSK-3, PTP1B) and the treatment of VaD was confirmed by the experimental studies on animals and reported separately in our recent publications.Dementia is a group of neurological diseases that usually occur in old age and are characterized by a progressive loss of cognitive function, leading to deterioration in social and professional abilities associated with memory loss, learning, communication, and reasoning. Ten million people develop dementia every year. According to Global Dementia Observatory (GDB) the number of people with dementia will increase from 50 million to 152 million by 2050. It is expected that the annual global cost of dementia will be doubled by 2030 up to US$ 2 trillion 1 .

show abstract

“…Initial PubMed search identified eleven case reports that described the use of icatibant as a treatment for ACE-inhibitor induced angioedema of the head and neck, with mixed results among cases. [3][4][5][6][7][8][9][10][11][12][13] Three of the results from the literature search included clinical trials, which offered more robust study designs and results than the aforementioned case reports. Baş et al first reported in 2015 that icatibant does offer potential benefits when used as a treatment for ACE-inhibitor induced angioedema of the head and neck.…”

Section: Related Literaturementioning

confidence: 99%

Icatibant is not an appropriate treatment option for ACE-inhibitor induced angioedema of the head and neck

Khaja

2018

Clin. Res. Pract.

View full text Add to dashboard Cite

show abstract

The role of icatibant—the B2 bradykinin receptor antagonist—in life-threatening laryngeal angioedema in the ED

Cited by 17 publications

References 16 publications

Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor–Induced Angioedema

Off-Label Use of Agents for Management of Serious or Life-threatening Angiotensin Converting Enzyme Inhibitor–Induced Angioedema

Combined network pharmacology and virtual reverse pharmacology approaches for identification of potential targets to treat vascular dementia

Icatibant is not an appropriate treatment option for ACE-inhibitor induced angioedema of the head and neck

Contact Info

Product

Resources

About